{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T14:40:38Z","timestamp":1767796838470,"version":"3.49.0"},"reference-count":86,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"unspecified","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,11,25]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiovascular diseases, overweight, type 2 diabetes and chronic kidney disease increase the risk of cardiovascular events.<\/jats:p>\n                    <jats:p>Glucagon-like peptide-1 analogues are recommended by the European Society of Cardiology and the American College of Cardiology to lower the risk of death and progression of cardiovascular disease in patients with cardiovascular disease and type 2 diabetes. Semaglutide, tirzepatide and liraglutide are approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of type 2 diabetes mellitus and overweight. CagriSema is currently not approved, but several phase III trials are ongoing.<\/jats:p>\n                    <jats:p>No previous systematic review has investigated the effects of semaglutide, tirzepatide, CagriSema and liraglutide, which may not be disease-specific, on hard binary outcomes for all trial populations at increased risk of cardiovascular events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analyses<\/jats:title>\n                    <jats:p>We will conduct a systematic review and search major medical databases (Cochrane Central Register of Controlled Trials, Medical Literature Analysis and Retrieval System Online, Excerpta Medica database, Latin American and Caribbean Health Sciences Literature, Science Citation Index Expanded, Conference Proceedings Citation Index\u2014Science) and clinical trial registries from their inception and onwards to identify relevant randomised trials. We expect to perform the literature search in December 2025. Two review authors will independently extract data and assess the risk of bias. We will include randomised trials assessing the effects of semaglutide, tirzepatide, CagriSema and\/or liraglutide in participants with an increased risk of cardiovascular events. The primary outcome will be all-cause mortality. Secondary outcomes will be myocardial infarction, stroke and all-cause hospitalisation. Data will be synthesised by aggregate data meta-analyses, Trial Sequential Analyses and network meta-analysis, risk of bias will be assessed with Cochrane Risk of Bias tool V. 2, and the certainty of the evidence will be assessed by Grading of Recommendations, Assessment, Development and Evaluations and the Confidence in Network Meta-Analysis approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This protocol does not present any results. Findings of this systematic review will be published in international peer-reviewed scientific journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42024623312.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-098205","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:25:20Z","timestamp":1765369520000},"page":"e098205","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of glucagon-like peptide-1 analogues on hard binary outcomes for patients at increased risk of cardiovascular events: a protocol for a systematic review with network meta-analysis and Trial Sequential Analysis"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9247-5245","authenticated-orcid":false,"given":"Christina Dam Bjerregaard","family":"Sillassen","sequence":"first","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Cardiology and Endocrinology, Slagelse Hospital, Slagelse, Denmark"},{"name":"Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6684-2070","authenticated-orcid":false,"given":"Pascal","family":"Faltermeier","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9837-1958","authenticated-orcid":false,"given":"Johanne Juul","family":"Petersen","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline Barkholt","family":"Kamp","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5511-4668","authenticated-orcid":false,"given":"Johannes","family":"Grand","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital - Amager-Hvidovre Hospital, Hvidovre, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Dominguez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"},{"name":"Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Fr\u00f8lich","sequence":"additional","affiliation":[{"name":"Innovation and Research Centre for Multimorbidity, Slagelse Hospital, Slagelse, Denmark"},{"name":"Section of General Practice, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Haulund","family":"G\u00e6de","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Endocrinology, Slagelse Hospital, Slagelse, Denmark"},{"name":"Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole","family":"Mathiesen","sequence":"additional","affiliation":[{"name":"Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, K\u00f8ge, Denmark"},{"name":"Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janus C","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"2026010703461829000_15.12.e098205.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.12.005"},{"key":"2026010703461829000_15.12.e098205.2","article-title":"Obesity and cardiovascular disease: Risk assessment, physical activity, and management of complications","volume":"23","author":"Perone","year":"2024","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"2026010703461829000_15.12.e098205.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.050686"},{"key":"2026010703461829000_15.12.e098205.4","unstructured":"World Health Organization . World Health Organization; Cardiovascular diseases (CVDs), 2025. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds)"},{"key":"2026010703461829000_15.12.e098205.5","unstructured":"Mattingly Q . Cardiovascular diseases. 2024. Available: https:\/\/www.who.int\/health-topics\/cardiovascular-diseases#tab=tab_1"},{"key":"2026010703461829000_15.12.e098205.6","unstructured":"WHO . The World Health Organization; Obesity and overweight 2025, 2025. Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"2026010703461829000_15.12.e098205.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01301-6"},{"key":"2026010703461829000_15.12.e098205.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.10.008"},{"key":"2026010703461829000_15.12.e098205.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2008.00853.x"},{"key":"2026010703461829000_15.12.e098205.10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"2026010703461829000_15.12.e098205.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-001-0719-z"},{"key":"2026010703461829000_15.12.e098205.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.05.022"},{"key":"2026010703461829000_15.12.e098205.13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"The Lancet"},{"key":"2026010703461829000_15.12.e098205.14","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1093\/eurheartj\/ehad774","article-title":"Correction to: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2026010703461829000_15.12.e098205.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.04.003"},{"key":"2026010703461829000_15.12.e098205.16","unstructured":"FDA approves new drug treatment for chronic weight management, first since 2014, 2021. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014"},{"key":"2026010703461829000_15.12.e098205.17","unstructured":"FDA . OZEMPIC (semaglutide) injection, for subcutaneous use. U.S.Food & Drug Administration. n.d. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/209637s012lbl.pdf"},{"key":"2026010703461829000_15.12.e098205.18","unstructured":"Ozempic semaglutide . European Medicines Agency, 2018. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ozempic"},{"key":"2026010703461829000_15.12.e098205.19","unstructured":"Wegovy semaglutide . European Medicines Agency, 2022. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/wegovy"},{"key":"2026010703461829000_15.12.e098205.20","unstructured":"MOUNJARO (tirzepatide) injection, for subcutaneous use, 2022. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf"},{"key":"2026010703461829000_15.12.e098205.21","unstructured":"FDA Approves New Medication for Chronic Weight Management, 2023. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-medication-chronic-weight-management"},{"key":"2026010703461829000_15.12.e098205.22","unstructured":"Mounjaro . European Medicines Agency, 2022. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mounjaro#product-info"},{"key":"2026010703461829000_15.12.e098205.23","unstructured":"U.S. Food & Drug Administration; Medication guide SAXENDA, 2010. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/206321s015lbl.pdf#page=30"},{"key":"2026010703461829000_15.12.e098205.24","unstructured":"U.S. Food & Drug Administration; Medication Guide VICTOZA, 2010. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/022341s039lbl.pdf#page=31"},{"key":"2026010703461829000_15.12.e098205.25","unstructured":"European Medicines Agency . Saxenda liraglutide, 2015. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/saxenda"},{"key":"2026010703461829000_15.12.e098205.26","unstructured":"European Medicines Agency . Victoza liraglutide. 2009. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/victoza"},{"key":"2026010703461829000_15.12.e098205.27","unstructured":"REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels, 2022. Available: https:\/\/clinicaltrials.gov\/study\/NCT05669755?term=redefine&page=2&rank=14"},{"key":"2026010703461829000_15.12.e098205.28","unstructured":"A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight (REDEFINE 1), 2022. Available: https:\/\/clinicaltrials.gov\/study\/NCT05567796?term=redefine&page=2&rank=18"},{"key":"2026010703461829000_15.12.e098205.29","unstructured":"A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight (REDEFINE 2), 2023. Available: https:\/\/clinicaltrials.gov\/study\/NCT05394519"},{"key":"2026010703461829000_15.12.e098205.30","unstructured":"A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight (REDEFINE 6), 2023. Available: https:\/\/clinicaltrials.gov\/study\/NCT05996848?term=redefine&page=2&rank=17"},{"key":"2026010703461829000_15.12.e098205.31","unstructured":"A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight, 2023. Available: https:\/\/clinicaltrials.gov\/study\/NCT06131437?cond=cagrisema&rank=4"},{"key":"2026010703461829000_15.12.e098205.32","unstructured":"A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor (REIMAGINE 2), 2023. Available: https:\/\/clinicaltrials.gov\/study\/NCT06065540?term=NCT06065540&rank=1"},{"key":"2026010703461829000_15.12.e098205.33","doi-asserted-by":"crossref","first-page":"102181","DOI":"10.1016\/j.eclinm.2023.102181","article-title":"Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"64","author":"Caruso","year":"2023","journal-title":"eClinicalMedicine"},{"key":"2026010703461829000_15.12.e098205.34","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes Rev"},{"key":"2026010703461829000_15.12.e098205.35","doi-asserted-by":"crossref","first-page":"116150","DOI":"10.1016\/j.biopha.2024.116150","article-title":"Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis","volume":"171","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"2026010703461829000_15.12.e098205.36","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/oby.24002","article-title":"Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis","volume":"32","author":"Pan","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"2026010703461829000_15.12.e098205.37","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-083039","article-title":"Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis","volume":"390","author":"Nong","year":"2025","journal-title":"BMJ"},{"key":"2026010703461829000_15.12.e098205.38","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"2026010703461829000_15.12.e098205.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-020-01070-z","article-title":"Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis","volume":"19","author":"Alfayez","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2026010703461829000_15.12.e098205.40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-094947","article-title":"Adverse effects with tirzepatide: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis","volume":"15","author":"Sillassen","year":"2025","journal-title":"BMJ Open"},{"key":"2026010703461829000_15.12.e098205.41","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"BMJ"},{"key":"2026010703461829000_15.12.e098205.42","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-4-1"},{"key":"2026010703461829000_15.12.e098205.43","unstructured":"Higgins J , Thomas J , Chandler J , et al . Cochrane handbook for systematic reviews of interventions. Cochrane, 2024. Available: www.training.cochrane.org\/handbook"},{"key":"2026010703461829000_15.12.e098205.44","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i65","article-title":"Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports","volume":"352","author":"Sharma","year":"2016","journal-title":"BMJ"},{"key":"2026010703461829000_15.12.e098205.45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002101","article-title":"Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of Orlistat: A Document Analysis","volume":"13","author":"Schroll","year":"2016","journal-title":"PLoS Med"},{"key":"2026010703461829000_15.12.e098205.46","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111470"},{"key":"2026010703461829000_15.12.e098205.47","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-018-0766-x","article-title":"The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors","volume":"7","author":"Hodkinson","year":"2018","journal-title":"Syst Rev"},{"key":"2026010703461829000_15.12.e098205.48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1353\/pbm.2019.0009","article-title":"Exploring the Asymmetrical Relationship Between the Power of Finance Bias and Evidence","volume":"62","author":"Howick","year":"2019","journal-title":"Perspect Biol Med"},{"key":"2026010703461829000_15.12.e098205.49","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-019-0983-y"},{"key":"2026010703461829000_15.12.e098205.50","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2026010703461829000_15.12.e098205.51","unstructured":"StataCorp . College Station, TX: StataCorp LLC; Stata statistical software: Release 18, 2023. Available: http:\/\/www.stata.com"},{"key":"2026010703461829000_15.12.e098205.52","unstructured":"Thorlund K , Engstr\u00f8m J , Wetterslev J , et al . Copenhagen; User manual for trial sequential analysis (TSA), 2017. Available: http:\/\/ctu.dk\/wp-content\/uploads\/2021\/03\/2017-10-10-TSA-Manual-ENG_ER.pdf"},{"key":"2026010703461829000_15.12.e098205.53","unstructured":"TSA - trial sequential analysis. Copenhagen Trial Unit, Available: http:\/\/www.ctu.dk\/tsa"},{"key":"2026010703461829000_15.12.e098205.54","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-067003","article-title":"Incorporating dose effects in network meta-analysis","volume":"376","author":"Watt","year":"2022","journal-title":"BMJ"},{"key":"2026010703461829000_15.12.e098205.55","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026010703461829000_15.12.e098205.56","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0442-1"},{"key":"2026010703461829000_15.12.e098205.57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2026010703461829000_15.12.e098205.58","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"2026010703461829000_15.12.e098205.59","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between\u2010study variance and its uncertainty in meta\u2010analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res Synth Methods"},{"key":"2026010703461829000_15.12.e098205.60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/jrsm.1316","article-title":"A comparison of heterogeneity variance estimators in simulated random\u2010effects meta\u2010analyses","volume":"10","author":"Langan","year":"2019","journal-title":"Res Synth Methods"},{"key":"2026010703461829000_15.12.e098205.61","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2380"},{"key":"2026010703461829000_15.12.e098205.62","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/31.1.140"},{"key":"2026010703461829000_15.12.e098205.63","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-10-90","article-title":"Evidence at a glance: error matrix approach for overviewing available evidence","volume":"10","author":"Keus","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"2026010703461829000_15.12.e098205.64","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026010703461829000_15.12.e098205.65","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"2026010703461829000_15.12.e098205.66","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780060325"},{"key":"2026010703461829000_15.12.e098205.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.013"},{"key":"2026010703461829000_15.12.e098205.68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.10.007"},{"key":"2026010703461829000_15.12.e098205.69","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn188"},{"key":"2026010703461829000_15.12.e098205.70","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn179"},{"key":"2026010703461829000_15.12.e098205.71","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-9-86","article-title":"Estimating required information size by quantifying diversity in random-effects model meta-analyses","volume":"9","author":"Wetterslev","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"2026010703461829000_15.12.e098205.72","doi-asserted-by":"publisher","DOI":"10.2147\/clep.s9242"},{"key":"2026010703461829000_15.12.e098205.73","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-011890","article-title":"False-positive findings in Cochrane meta-analyses with and without application of trial sequential analysis: an empirical review","volume":"6","author":"Imberger","year":"2016","journal-title":"BMJ Open"},{"key":"2026010703461829000_15.12.e098205.74","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"2026010703461829000_15.12.e098205.75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.09.011"},{"key":"2026010703461829000_15.12.e098205.76","first-page":"677","article-title":"Letters, numbers, symbols and words: how to communicate grades of evidence and recommendations","volume":"169","author":"Sch\u00fcnemann","year":"2003","journal-title":"CMAJ"},{"key":"2026010703461829000_15.12.e098205.77","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: An approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"key":"2026010703461829000_15.12.e098205.78","doi-asserted-by":"crossref","DOI":"10.1002\/cl2.1080","article-title":"CINeMA: Software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst Rev"},{"key":"2026010703461829000_15.12.e098205.79","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwae260"},{"key":"2026010703461829000_15.12.e098205.80","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network Meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"The Stata Journal: Promoting Communications on Statistics and Stata"},{"key":"2026010703461829000_15.12.e098205.81","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2017047","article-title":"Network meta-analysis: application and practice using Stata","volume":"39","author":"Shim","year":"2017","journal-title":"Epidemiol Health"},{"key":"2026010703461829000_15.12.e098205.82","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"key":"2026010703461829000_15.12.e098205.83","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3767"},{"key":"2026010703461829000_15.12.e098205.84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016"},{"key":"2026010703461829000_15.12.e098205.85","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"2026010703461829000_15.12.e098205.86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.02.016"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-098205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:47:31Z","timestamp":1767786451000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-098205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":86,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,10]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2024-098205"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-098205","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}